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Abstract: Selective intra-arterial chemotherapy (IAC) has been adopted by many ocular 
  oncology centers to treat advanced intraocular retinoblastoma. In this report, we describe two 
patients with unilateral intraocular retinoblastoma and persistent vitreous seeding, who were 
treated with IAC after failed systemic chemotherapy. Despite multiple sessions and increasing 
dosage of drug delivery, vitreous seeding in these cases failed to respond to IAC, and ultimately 
both eyes were enucleated for tumor control. Based on the histopathologic findings in these two 
cases, IAC appears to have limitations in treating persistent vitreous seeding in eyes which have 
failed systemic chemotherapy. Possible causes for failure of IAC to treat persistent vitreous 
seeding include poor vitreous penetration, inactive state of tumor seeds within the avascular 
vitreous cavity, and chemotherapeutic drug resistance.
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Introduction
Intra-arterial infusion of chemotherapy (IAC) has been recognized as a viable new 
method for treating advanced intraocular retinoblastoma.1–4 When compared to intra-
venous chemotherapy, potential advantages of selective IAC include the reduction 
of systemic effects such as myelosuppression, immunosuppression and the risk of 
secondary leukemia.5 Compared to external beam radiation, IAC can be used to treat 
children below age 12 months without concerns regarding local side effects such as 
orbital hypoplasia and the risk of secondary head and neck cancers later in life.6 Gobin 
et al have demonstrated globe salvage rates as high as 82% with IAC in primary cases 
with advanced intraocular tumors.2 In this report, we describe two patients with uni-
lateral intraocular retinoblastoma and persistent vitreous seeding, who were treated 
with IAC after failed systemic chemotherapy. Despite multiple sessions and increasing 
dosage of drug delivery, vitreous seeding in these cases failed to respond to IAC, and 
ultimately both eyes were enucleated for tumor control.
Case description
Case one 
A one-month-old child born three weeks premature was diagnosed with a left retinal 
tumor during a screening examination. Fundus evaluation revealed a left macular tumor 
which was whitish in appearance with fine retinal vasculature   (Figure 1A). Based on 
her other clinical findings (symphalangism, pelviectasis, paired ribs, facial dysmor-
phic features), she was diagnosed with unilateral retinoblastoma in the setting of 13q 
deletion syndrome. The left eye was classified as having a Group C tumor based on Clinical Ophthalmology 2011:5
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Figure 1 (A) One-month-old child with unilateral retinoblastoma and a left macular 
tumor.  (B)  excellent  regression  of  the  tumor  after  three  sessions  of  systemic 
chemotherapy, causing complete calcification of the macular lesion. (C) Tumor 
recurrence along temporal edge of the tumor, with associated vitreous seeding. 
(D)  excellent  regression  of  the  retinal  tumor  recurrence  but  no  response  by 
vitreous seeding after systemic chemotherapy.
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Figure 2 (A) Diffuse periocular edema following intra-arterial infusion of melphalan, 
which resolved without sequelae. (B) Fundus photograph showing progression of 
vitreous seeding despite two sessions of intra-arterial chemotherapy.
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Figure 3 (A) Gross photograph of enucleated eye showing a calcific scar of the 
regressed  macular  retinoblastoma  and  extensive  vitreous  seeding.  (B)  section 
through the macula with the optic nerve to the right of the photograph. Macular 
scar in area without calcification; the scar consists of glial cell proliferation and 
retinal pigment epithelium hyperplasia. in addition, a portion of the retina has shifted 
into the choroid through a break in Bruch’s membrane (hematoxylin-eosin, original 
magnification 100×). (C) Temporal, equatorial retina with numerous tumor seeds 
(basophilic cells, see arrow) in the overlying vitreous (hematoxylin-eosin, original 
magnification 100×). (D) Vitreous seeds with markedly positive nuclear reaction to 
Ki67 (original magnification 200×).
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the macular location and the presence of localized seeding. 
She received three sessions of systemic chemotherapy using 
a three drug regimen (carboplatin, etoposide, vincristine), 
with excellent clinical regression of the tumor (Figure 1B). 
There was complete calcification of the tumor, and it was 
decided to carefully observe the patient rather than perform 
laser treatment due to its macular location. The patient was 
then lost to follow-up when her family took her to India for 
approximately 9 months. When she finally returned to our 
institution, a tumor recurrence along the temporal edge of the 
macular scar was noted. There was also diffuse vitreous seed-
ing arising from this area of tumor recurrence (Figure 1C). 
The patient was treated with two additional courses of 
systemic chemotherapy (topotecan and cyclophosphamide) 
with excellent regression of the retinal tumor recurrence, but 
there was no response by the vitreous seeding (Figure 1D). 
The patient was then treated with two sessions of IAC; the 
first with 5 mg of melphalan and the second (1 month later) 
with 8 mg of melphalan. After the second session of IAC, 
the patient developed diffuse periocular edema (Figure 2A), 
which resolved within 1 week. Unfortunately, the vitreous 
seeding appeared to increase in severity (Figure 2B), and the 
left eye was enucleated to prevent tumor spread, approxi-
mately 2 1/2 years after initial diagnosis.
Gross examination of the sectioned enucleated eye 
showed extensive tumor seeding within the vitreous cavity 
(Figure 3A). Histopathologic examination showed complete 
regression and calcification of the macular tumor. (Figure 3B). 
The tumor was replaced by a scar comprising glial cells and 
retinal pigment epithelial proliferation. Bruch’s membrane 
was broken and a portion of the retina had shifted through 
this break into the choroid. Numerous tumor seeds were seen 
lying on the internal limiting membrane (Figure 3C), but the 
retina away from the macular scar was otherwise normal in 
appearance. The vitreous contained numerous tumor nodules 
of small, basophilic cells with a high nuclear to cytoplasmic 
ratio. The diffuse vitreous seeding demonstrated 80% posi-
tive staining with Ki67 (Figure 3D), an immunohistochem-
istry marker for cellular proliferation.7 No histopathologic 
abnormalities were noted within the cornea, iris, choroid, 
sclera or optic nerve (data not shown).
Case two
A four-year-old boy was referred with persistent uni-
lateral retinoblastoma involving the right eye after sys-
temic chemotherapy. The patient had received five total 
courses of systemic chemotherapy at another   institution; Clinical Ophthalmology 2011:5
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Figure  4  (A)  Fundus  photograph  of  the  right  eye  showing  partially  regressed 
superotemporal tumor and vitreous seeds overlying the macula. (B) same view of 
right fundus showing no regression of the vitreous seeds despite three sessions of 
intra-arterial chemotherapy.
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the first three courses with vincristine, etoposide, and 
  carboplatin, and the final two courses with topotecan and 
  cyclophosphamide. The patient had no family history of 
retinoblastoma and his past medical history was otherwise 
negative. The patient’s vision measured 20/30 OD and 
20/15 OS. Fundus examination revealed a partially regressed 
supero-temporal tumor, with multiple vitreous seeds overly-
ing the macula (Figure 4A). He was treated with three ses-
sions of IAC; the first with 5 mg of melphalan, the second 
with 8 mg of melphalan, and the third with 4 mg of melphalan 
and 30 mg of carboplatin. After the first IAC infusion, his 
white blood cell count decreased from 5600 to 3700 but he did 
not require admission. Visual acuity after the IAC infusions 
ranged between 20/30–20/50 in the right eye. Examination 
under anesthesia after the third session of IAC showed a 
slight increase in the vitreous seeding, and no response by 
the main tumor mass (Figure 4B). Five months following 
the initial IAC infusion, enucleation was performed due to 
concerns regarding the persistently active tumor.
Gross evaluation of the sectioned enucleated eye revealed 
a 5 × 5 mm mass superotemporally on the retina with calci-
fications (Figure 5A). The mass was differentiated, contain-
ing cells with small bland nuclei and relatively abundant 
eosinophilic cytoplasm (Figure 5B). No fleurettes, rosettes or 
mitotic figures were seen. Scattered areas of glial cells were 
seen adjacent to the tumor and within the tumor. Occasional 
vitreous seeds were found in the vitreous near the retina. 
The retina otherwise appeared normal in all quadrants. The 
immunohistochemical stain for Ki-67, a cellular prolifera-
tion marker, revealed no positive reactions in either the main 
tumor or the vitreous seeds, consistent with their differenti-
ated appearance (Figure 5C).
Comment
Selective intra-arterial chemotherapy (IAC) has been adopted 
by many ocular oncology centers to treat advanced intraocu-
lar retinoblastoma.1–4 In some centers, IAC has become 
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Figure 5 (A) Gross photograph of enucleated eye showing main superotemporal 
tumor  and  vitreous  seeds  overlying  the  macula  (arrow).  (B)  The  main  tumor 
consisting of well-differentiated cells with abundant cytoplasm (hematoxylin-eosin, 
original magnification 400×). (C) A vitreous seed containing differentiated cells, with 
negative staining with Ki67 (hematoxylin-eosin, original magnification 400×).
the primary modality for treating advanced tumors, while 
in other institutions IAC is used mainly as salvage therapy 
after failed systemic chemotherapy and/or radiation.2,3 The 
ocular effects of directly infusing the ophthalmic artery with 
chemotherapy agents are still being studied. Local transient 
side effects have been reported including peri-orbital swelling 
and erythema, temporary eyelash loss and more rarely, retinal 
arterial occlusion.8–10 Brodie and colleagues have demonstrated 
through electrophysiologic testing that some eyes after IAC 
have preserved and even improved ERG readings.11 However, 
Vajzovic et al reported retinopathy and vitreous hemorrhage 
in three of their first eleven eyes treated at the University of 
Miami.3,9 There has also been a recent report of choroidal artery 
occlusion and retinal emboli formation following IAC.10
We report two children with intraocular retinoblastoma 
who underwent enucleation following failed systemic chemo-
therapy and multiple infusions with IAC. In the original series 
of nine patients reported by Abramson, the two eyes enucle-
ated after IAC did not show evidence of ocular   toxicity.1 
A histopathologic report from Vajzovic and colleagues 
showed no evidence of toxicity to the retina, optic nerve, 
choroid or vascular structures.12 Graeber and colleagues 
recently reported pathologic findings in ten eyes that were 
enucleated for tumor growth after IAC.13 They also did not 
identify any specific evidence of ocular toxicity attributed 
to IAC, although nine of the ten eyes had received prior 
multimodal treatment such as external beam radiotherapy 
and laser therapy. In our two cases, there was no previous 
history of any local therapy being delivered to the globes. Clinical Ophthalmology
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The two eyes were treated with doses of melphalan as high 
as 8 mg, utilizing an infusion technique identical to the one 
described by Abramson and colleagues.1 There was no evi-
dence of ocular toxicity on histopathologic examination, as 
evidenced by the lack of degeneration of the retina and optic 
nerve in areas uninvolved by tumor. Although electrophysi-
ologic testing was not performed, the older patient in our case 
series demonstrated fairly well-preserved visual acuity after 
all three of his IAC infusions. Based on the limited evidence 
to date, it does not appear that IAC causes anatomic damage 
to the globe in the absence of a retinal occlusive event.
In both of our cases, vitreous seeding did not respond to 
treatment with IAC, despite escalating doses of melphalan 
(cases one and two) and even multiple drug combinations 
(case two). We used doses of melphalan as high as 8 mg per 
treatment in our two cases, which is slightly higher than the 
7.5 mg dose reported by both Gobin et and Vajzovic.2,12 Both 
patients developed temporary side effects following IAC 
(periocular edema, neutropenia), but the vitreous seeding 
persisted and even continued to progress. It is noteworthy that 
all three of the eyes reported by Vajzovic et al which were 
removed for poor response after systemic chemotherapy and 
salvage IAC also had vitreous seeding.12 Based on a limited 
number of cases to date, IAC appears to have limitations in 
treating persistent vitreous seeding in eyes which have failed 
systemic chemotherapy. Possible causes for failure of IAC 
to treat persistent vitreous seeding include poor vitreous 
penetration, inactive state of tumor seeds within the avascular 
vitreous cavity, and chemotherapeutic drug resistance. The 
decision to use IAC for any eye with retinoblastoma must 
be individualized based on several factors including unilat-
eral or bilateral tumor involvement, the availability of other 
treatment options, and whether the eye has significant visual 
potential. For a patient with unilateral retinoblastoma and 
recalcitrant vitreous seeding after systemic chemotherapy, 
multiple sessions of IAC with escalating doses of melphalan 
may not be advisable given that enucleation is typically 
curative in these cases.
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